| Methods |
cross‐over trial, mean treatment duration 53 days for both dig & pla; endpoints—"heart failure score," CT ratio, LVED, EF |
| Participants |
25 pts; mean age 61; 72% male; 88% on diuretics; mean EF 0.29; prior dig Rx in 96%; dx—60% ischemic, 24% cardiomyopathic, 16% hypertrophic cardiomyopathy |
| Interventions |
dig dosage titrated to mean serum level of 1.15 ng/mL, mean dig dosage 0.435 mg/d |
| Outcomes |
for dig versus pla, "heart failure score" 2.0 & 3.6 (P < 0.05), CT ratio 0.51 & 0.53 (P value 0.00027), LVED 31 & 33 mm/sq m (P value 0.0026), EF 0.30 & 0.29 (P value NS) |
| Notes |
blind allocation—yes
blinded to outcomes—yes
baselines comparable—NA
loss to follow‐up—?
dig titrated to level—yes |
| Risk of bias |
| Bias |
Authors' judgement |
Support for judgement |
| Allocation concealment (selection bias) |
Low risk |
A—Adequate |
